Effects of vitamin D supplementation on plasma aldosterone and renin

• Verfasst von: Grübler, Martin R. [VerfasserIn]
• Verfasst von: März, Winfried [VerfasserIn]
• Titel: Effects of vitamin D supplementation on plasma aldosterone and renin
• Titelzusatz: a randomized placebo-controlled trial
• Verf.angabe: Martin R. Grübler, Martin Gaksch, Katharina Kienreich, Nicolas Verheyen, Johannes Schmid, Bríain W. J. Ó Hartaigh, Georg Richtig, Hubert Scharnagl, Andreas Meinitzer, Burkert Pieske, Astrid Fahrleitner‐Pammer, Winfried März, Andreas Tomaschitz, Stefan Pilz
• E-Jahr: 2016
• Jahr: 21 April 2016
• Umfang: 6 S.
• Fussnoten: Gesehen am 11.03.2020
• Titel Quelle: Enthalten in: The journal of clinical hypertension
• Ort Quelle: Hoboken, NJ : Wiley, 2001
• Jahr Quelle: 2016
• Band/Heft Quelle: 18(2016), 7, Seite 608-613
• ISSN Quelle: 1751-7176
• DOI: doi:10.1111/jch.12825
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1692278916

Abstract

Increasing evidence describes a possible interplay between vitamin D insufficiency with increased aldosterone. The authors sought to evaluate the effect of vitamin D supplementation on plasma aldosterone concentration (PAC) in patients with hypertension and 25-hydroxyvitamin D[25(OH)D] insufficiency. The Styrian Vitamin D Hypertension Trial was a single-center, double-blind, placebo-controlled randomized clinical trial conducted from 2011 to 2014. Two hundred patients with arterial hypertension and 25(OH)D levels <30 ng/mL were enrolled. Study participants were randomized to receive either 2800 IU of vitamin D3 or placebo. The present investigation is a post hoc analysis using analysis of covariance adjusting for baseline differences. A total of 188 participants (mean±standard deviation age, 60.1±11.3 years; 47% women; 25(OH)D, 21.2±5.6 ng/mL) completed the trial. Mean differences between baseline and follow-up PAC in the control and intervention arm were +3.3 ng/dL and +0.9 ng/dL, respectively (P=.04). The findings indicate that vitamin D3 supplementation significantly decreases PAC in patients with arterial hypertension and 25(OH)D insufficiency.